Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for CASODEX
- Bicalutamide Therapy in Young Women With NAFLD and PCOS
- Phase II Dutasteride in Combination With CAB vs CAB in SDC
- Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Trial to Promote Recovery From COVID-19 With Endocrine Therapy
- Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
- Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
- Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
- Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
- Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
- Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
- Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
- A Study of Definitive Therapy to Treat Prostate Cancer
- FDHT PET and Bicalutamide in Metastatic Breast Cancer
- Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
- Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy
- Micro RNAs to Predict Response to Androgen Deprivation Therapy
- Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
- LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
- Study of Dasatinib, Androgen Deprivation Therapy and Radiation
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Degarelix Neo-Adjuvant Radical Prostatectomy Trial
- Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
- Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
- Bioequivalence of Bicalutamide New Formulation in Japan
- Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects
- Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
- A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
- Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
- Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
- Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
- Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
- Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
- Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions
- Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting Conditions
- Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
- Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Conditions
- Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions
- Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
- Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
- Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
- Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
- Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
- Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
- Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
- CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
- (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
- Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
- Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
- R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
- Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
- Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
- Casodex - Nolvadex Combination
- Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
- Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
- RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
- Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
- Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
- Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
- Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.
- Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
- Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
- Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
- External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
- Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
- Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
- Casodex/Zoladex Biomarkers in Localised Prostate Cancer
- Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
- Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
- Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
- Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
- Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
- A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
- Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
- Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
- Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
- Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
- S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
- Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
- Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
- Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
- Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
Clinical trials list
click for details